Key Hereditary Angioedema Treatment Market Players:
- Attune Pharmaceuticals
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- BioCryst Pharmaceuticals, Inc.
- Biomarin
- CSL Behring LLC
- Intellia Therapeutics
- Ionis Pharmaceuticals
- KalVista Pharmaceuticals, Inc.
- Pharming Healthcare, Inc.
- Pharvaris
The hereditary angioedema treatment market is dominated is dominated by several key companies, significantly shaping the landscape of innovative treatments. These companies focus on both acute and prophylactic treatments. In September 2021, Cycle Pharmaceuticals announced the launch of SAJAZIR Injection, a new treatment option for patients affected by Hereditary Angioedema. The treatment has been approved by the US Food and Drug Administration (FDA). Competitive dynamics in the hereditary angioedema treatment market have intensified in the last few years. Companies are seeking to differentiate their products through improved efficacy, safety, and ease of use. Some of these prominent companies are:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of hereditary angioedema treatment is evaluated at USD 4.82 billion.
Hereditary Angioedema Treatment Market size was valued at USD 4.48 billion in 2025 and is expected to reach USD 10.04 billion by 2035, expanding at around 8.4% CAGR during the forecast period i.e., between 2026-2035.
North America leads the Hereditary Angioedema Treatment market with a 53.5% share, propelled by the rise in precision medicine and personalized healthcare demand, fostering innovation through 2026–2035.
Key players in the market include BioCryst Pharmaceuticals, Inc., Biomarin, CSL Behring LLC.
